• Beteiligung an „Cells in Motion“

    • Forschungsinteressen: tumor progression, metastasis, tumor microenvironment, extracellular vesicles, Wnt signaling
    • Mitglied im Graduiertenprogramm CiM-IMPRS

  • Publikationen im Forschungsschwerpunkt „Zelldynamik und Bildgebung“

    2024

    Kockwelp J, Thiele S, Bartsch J, Haalck L, Gromoll J, Schlatt S, Exeler R, Bleckmann A, Lenz G, Wolf S, Steffen B, Berdel WE, Schliemann C, Risse B, Angenendt L. Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears. Blood Adv 2024;8: 70-79. Abstract

    2021

    Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, Treiber H, Ruhwedel T, Schatlo B, von der Brelie C, Wiemann S, Pukrop T, Beissbarth T, Binder C, Bleckmann A. WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. J Exp Clin Cancer Res 2021;40: 395. Abstract

    2018

    Fromme JE, Schmitz K, Wachter A, Grzelinski M, Zielinski D, Koppel C, Conradi L-C, Homayounfar K, Hugo T, Hugo S, Lukat L, Ruschoff J, Strobel P, Ghadimi M, Beissbarth T, Reuter-Jessen K, Bleckmann A, Schildhaus H-U. FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis. Oncotarget 2018;9: 32204-32218. Abstract

    2017

    Bayerlova M, Menck K, Klemm F, Wolff A, Pukrop T, Binder C, Beissbarth T, Bleckmann A. Ror2 Signaling and Its Relevance in Breast Cancer Progression. Front Oncol 2017;7: 135. Abstract
    Menck K, Bleckmann A, Wachter A, Hennies B, Ries L, Schulz M, Balkenhol M, Pukrop T, Schatlo B, Rost U, Wenzel D, Klemm F, Binder C. Characterisation of tumour-derived microvesicles in cancer patients' blood and correlation with clinical outcome. J Extracell Vesicles 2017;6: 1340745. Abstract

    2016

    Bleckmann A, Conradi L-C, Menck K, Schmick NA, Schubert A, Rietkotter E, Arackal J, Middel P, Schambony A, Liersch T, Homayounfar K, Beissbarth T, Klemm F, Binder C, Pukrop T. beta-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis 2016;33: 309-323. Abstract